LLM startup Hippocratic AI has secured $141 million in Series B funding, raising its valuation to $1.64 billion. This latest milestone, achieved just nine months after its Series A, reflects strong investor confidence in the company’s innovative approach to healthcare AI.
The round was led by Kleiner Perkins, known for backing tech giants like Google and Amazon, with support from existing investors, including A16z, General Catalyst, and NVIDIA, alongside healthcare partners like Universal Health Services (UHS) and WellSpan Health.
Hippocratic AI has created a safety-focused Large Language Model (LLM) aimed at improving global healthcare accessibility and outcomes by delivering advanced healthcare expertise to individuals worldwide.
The company has already deployed its genAI agents across a range of healthcare organisations, including Cincinnati Children’s, Honor Health, OhioHealth, and Fraser Health in Canada. These agents have completed hundreds of thousands of patient interactions, achieving an impressive average satisfaction rating of 8.7 out of 10.
Founding partners like UHS and Memorial Hermann worked closely with the company to ensure its models met stringent safety benchmarks, culminating in the release of Polaris 2.0 earlier this year. This updated model increased its intelligence capacity from 1.1 trillion to 3.7 trillion parameters, achieving safety levels equivalent to those of a human nurse.
The new capital will drive expansion into new markets such as EMEA, Southeast Asia, and Latin America, as well as broaden the company’s reach to additional verticals, including pharmaceuticals and payors. Hippocratic AI’s Polaris constellation architecture, designed for non-diagnostic, patient-facing clinical tasks, remains central to its mission of enhancing patient outcomes through safety-focused innovation.
Adding to its innovations, Hippocratic AI recently unveiled an AI Agent App Store, inviting licensed clinicians to design customised AI agents for specific use cases.